期刊
MOLECULAR PSYCHIATRY
卷 24, 期 3, 页码 364-377出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41380-018-0021-9
关键词
-
资金
- Fonds de Recherche du Quebec en Sante (FRQS) [35059]
- Canadian Institutes of Health Research (CIHR) [MOP326050]
- Universite Laval
- Fondation du CHU de Quebec
There is compelling evidence that the pathophysiology of many neurodegenerative diseases includes dysregulation of the immune system, with some elements that precede disease onset. However, if these alterations are prominent, why have clinical trials targeting this system failed to translate into long-lasting meaningful benefits for patients? This review focuses on Huntington's disease, a genetic disorder marked by notable cerebral and peripheral inflammation. We summarize ongoing and completed clinical trials that have involved pharmacological approaches to inhibit various components of the immune system and their pre-clinical correlates. We then discuss new putative treatment strategies using more targeted immunotherapies such as vaccination and intrabodies and how these may offer new hope in the treatment of Huntington's disease as well as other neurodegenerative diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据